Hoth Therapeutics, INC 10-Q quarterly reports

Hoth Therapeutics reported a wider net loss in Q3 2025 due to increased R&D and administrative expenses, while securing additional capital through warrant exercises and an ATM offering.

Hoth Therapeutics reported a significant increase in net loss for Q2 2025, driven by higher research and development expenses, while bolstering its cash position through financing activities.

Hoth Therapeutics reports a net loss for Q1 2025, but strengthens its cash position through warrant exercises and ATM offerings.

Hoth Therapeutics, a clinical-stage biopharmaceutical company, released its third quarter 2024 financial results, highlighting ongoing research and development efforts and a decrease in net loss compared to the same period last year.

Hoth Therapeutics reports a net loss of $3.7 million for the six months ended June 30, 2024, with a decrease in research and development expenses and an increase in general and administrative costs.

Hoth Therapeutics reported a net loss of $2.0 million for the first quarter of 2024, with a focus on advancing its clinical-stage biopharmaceutical programs.